PLC Systems Inc. is touting preliminary results from a clinical study of its RenalGuard anti-contrast-induced nephropathy treatment.
CIN is a form of acute renal failure caused by exposure to contrast media agents during image-guided cardiology and radiology procedures. The Franklin, Mass.-based company said data on 43 patients at high risk for kidney failure indicate that none of the patients treated with RenalGuard acquired the malady.
Seventeen percent of patients who were treated with overnight hydration did acquire CIN, however, and two required temporary renal replacement therapy. Acquiring CIN has been found to lead to a range of serious and potentially deadly outcomes in patients who already have compromised kidney function.
President and CEO Mark Tauscher said the company is pleased with the preliminary results, though it expects higher CIN rates as the study expands to 120 patients.
PLC cut its net loss in half despite a 6.9 percent revenues slide during the second quarter and inked a RenalGuard distribution deal in South Asia earlier this month.